Latest News and Press Releases

Spexis Announces Changes to the Executive Committee

Spexis to host business update conference call on October 9, 2023

Spexis provides business update and announces financial results for the first half of 2023

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle...

ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of...

Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in...

Ad hoc announcement pursuant to Art. 53 LR Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-patient-in expected in June 2023Commitment...

Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward...

Cash position to finance operations extended into January 2023Resources focused on advancing lead program, Phase 3 ColiFin®Assessment of balixafortide development options continues; balixafortide...